Hikma Pharmaceuticals (OTCMKTS:HKMPF) & Sandoz Group (OTCMKTS:SDZNY) Head-To-Head Contrast

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and Sandoz Group (OTCMKTS:SDZNY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Dividends

Hikma Pharmaceuticals pays an annual dividend of $0.96 per share and has a dividend yield of 3.5%. Sandoz Group pays an annual dividend of $0.44 per share and has a dividend yield of 0.8%.

Risk and Volatility

Hikma Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Sandoz Group has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Earnings and Valuation

This table compares Hikma Pharmaceuticals and Sandoz Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	$3.13 billion	1.97	$359.00 million	N/A	N/A
Sandoz Group	$10.36 billion	2.30	$1.00 million	N/A	N/A

Hikma Pharmaceuticals has higher earnings, but lower revenue than Sandoz Group.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Hikma Pharmaceuticals and Sandoz Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0	0	1	1	3.50
Sandoz Group	0	2	0	0	2.00

Profitability

This table compares Hikma Pharmaceuticals and Sandoz Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	N/A	N/A	N/A
Sandoz Group	N/A	N/A	N/A

Insider and Institutional Ownership

0.1% of Sandoz Group shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Hikma Pharmaceuticals beats Sandoz Group on 5 of the 9 factors compared between the two stocks.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.